RxDoctor Payments Data

Alton Hendon, MD

Family Medicine · Montgomery, ALNPI 1902887649

Payments from drug & device makers

$7,425in general payments, 2019–2025

Across 454 payments — averaging $16.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$969
  • AstraZeneca$729
  • Pfizer$727
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$594
  • Amgen$508
  • Lilly USA, LLC$487
  • plus $3K from 36 others

What the payments were for

  • Food & beverage$7,36099%
  • Education$651%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,425 in reported general payments places this provider in the 85th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$211,505
Medicare patients
298
Services billed
8,052

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin145$153,481
EliquisApixaban117$107,968
OzempicSemaglutide70$94,166
JanuviaSitagliptin Phosphate73$58,192
FarxigaDapagliflozin Propanediol42$46,483
MounjaroTirzepatide23$35,243
Janumet XrSitagliptin Phos/Metformin Hcl26$30,235
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$22,352
TrulicityDulaglutide11$21,451
XareltoRivaroxaban37$20,859
RybelsusSemaglutide16$19,074
Tresiba Flextouch U-200Insulin Degludec22$18,702
LinzessLinaclotide27$18,633
Repatha SureclickEvolocumab19$16,293
JanumetSitagliptin Phos/Metformin Hcl19$14,227

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Glyxambi$36$160,344157 claims
Novo NordiskOzempic, Rybelsus$969$113,24086 claims
PfizerEliquis, Premarin$727$113,023131 claims
MerckJanuvia, Janumet Xr, Janumet$128$102,654118 claims
Lilly USA, LLCMounjaro, Trulicity$487$56,69334 claims
AstraZenecaFarxiga$729$46,48342 claims
GSKTrelegy Ellipta, Breo Ellipta$277$35,35650 claims
AbbVieLinzess, Synthroid$442$32,289164 claims
Johnson & JohnsonXarelto$286$20,85937 claims
Astellas Pharma US IncMyrbetriq$241$13,53817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Montgomery

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →